Advertisement
Research Article

An Accurate Prostate Cancer Prognosticator Using a Seven-Gene Signature Plus Gleason Score and Taking Cell Type Heterogeneity into Account

  • Xin Chen,

    Affiliation: Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, United States of America

    X
  • Shizhong Xu,

    Affiliation: Department of Genetics and Geneticist Botany and Plant Sciences, University of California Riverside, Riverside, California, United States of America

    X
  • Michael McClelland,

    Affiliations: Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, United States of America, Vaccine Research Institute of San Diego, San Diego, California, United States of America

    X
  • Farah Rahmatpanah,

    Affiliation: Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, United States of America

    X
  • Anne Sawyers,

    Affiliation: Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, United States of America

    X
  • Zhenyu Jia mail,

    zjia@uci.edu (ZJ); dmercola@uci.edu (DM)

    Affiliation: Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, United States of America

    X
  • Dan Mercola mail

    zjia@uci.edu (ZJ); dmercola@uci.edu (DM)

    Affiliation: Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, United States of America

    X
  • Published: September 28, 2012
  • DOI: 10.1371/journal.pone.0045178

About the Authors

Xin Chen, Michael McClelland, Farah Rahmatpanah, Anne Sawyers, Zhenyu Jia, Dan Mercola
Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, United States of America
Shizhong Xu
Department of Genetics and Geneticist Botany and Plant Sciences, University of California Riverside, Riverside, California, United States of America
Michael McClelland
Vaccine Research Institute of San Diego, San Diego, California, United States of America

Corresponding Authors

Competing Interests

D. Mercola and M. McClelland are board members of Proveri Inc. which has a license from the Regents of the University of California for the development of clinical assays for prostate cancer. The other authors declare they have no conflict of interest with this publication. This does not alter the authors’ adherence to all of PLOS ONE’s policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: XC ZJ DM. Performed the experiments: XC AS ZJ. Analyzed the data: XC SX ZJ FR. Wrote the paper: XC ZJ MM DM.